>>> US Gapping up

Gapping up

Gapping up
In reaction to earnings/guidance:

  • CTLT +1%

Other news:

  • KDNY +65.1% (to be acquired by Novartis (NVS) for $40.00 per share upfront plus contingent value right of up to $4.00 per share)
  • CCF +9.7% (report it's seeking a sale, according to WSJ)
  • NTLA +7% (Clinical Data from Phase 1 Study of NTLA-2002)
  • GRCL +6% (Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin's Lymphoma at EHA2023, Highlighting 100% Overall Response Rate)
  • HUMA +4.4% (files for 1,333,334 shares of common stock by selling shareholders)
  • ORCL +4.2% (report it has invested in Cohere, an AI startup that competes with OpenAI, according to TheInformation)
  • IPHA +3.7% (to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma; Highlights Proprietary Tetra-specific ANKET NK Cell Engager IPH6501 at the EHA 2023 Congress)
  • CLDX +3.6% (Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023)
  • CLLS +3.4% (Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA))
  • AAC +3% (Ares Acquisition Corp. and X-energy provide strategic update to business combination terms)
  • MRKR +2.8% (reports first lymphoma patient treated with MT-601 in Phase 1 clinical trial)
  • SCU +2.5% (files $600 mln mixed shelf securities offering )
  • BIIB +2.5% (FDA Advisory Committee votes unanimously to confirm the clinical benefit of LEQEMBI)
  • OCUL +2.4% (Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI)
  • NKTX +2.4% (Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma)
  • KURA +2% (Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib)
  • KYMR +2% (Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413)
  • RGLD +1.3% (announces commitment to acquire Gold/Platinum/Palladium and Copper/Nickel Royalties on producing Serrote and Santa Rita Mines in Brazil)
  • ME +1% (discloses in SEC filing that its CEO approved a workforce reduction involving approximately 75 employees; severance and benefit continuation charges estimated to be about $3.5 mln)
  • TEVA +1% (Teva Pharma and Alvotech (ALVO) Secure U.S. license date for AVT04, a proposed biosimilar to Stelara)
  • TECK +1% (confirms Glencore's (GLNCY) is one of a number of proposals under consideration related to steelmaking coal business)

Analyst comments:

  • RETA +4.5% (upgraded to Outperform from Market Perform at SVB Securities)
  • VTRU +4.3% (upgraded to Outperform from Neutral at Bradesco BBI)
  • AZO +1.3% (upgraded to Outperform from In-line at Evercore ISI)